The Inhibitor of Apoptosis proteins (IAPs) are emerging as promising targets for autoimmune and inflammatory diseases. Data generated by Aegera demonstrate that IAPs play important roles in the modulation of key cell types which contribute to the pathophysiology of specific autoimmune/inflammatory diseases and that pharmacological inhibition of specific IAPs is a novel approach which may provide therapeutic benefit in several diseases. Aegera is currently exploring the use of its IAP inhibitors in non-oncology indications, and has generated very promising POC data in relevant preclinical models of autoimmune/inflammatory diseases.